Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
The KCNQ potassium channels are neuronal modulators which combine with other KQT or KCNE channels to form heteromultimers. XE 991 is a blocker of KCNQ channels that potently inhibits KCNQ1 and 2 homomeric channels (IC50 = 0.75 and 0.71 µM, respectively) as well as KCNQ2+3 heteromultimers (IC50 = 0.6 µM).1 It much less effectively blocks eag, erg, and elk channels. The effectiveness of XE 991 against KCNQ channels depends on partners or accessory proteins.2 Through these actions, XE 991 enhances acetylcholine release from rat brain slices (EC50 = 490 nM) and shows good in vivo potency and duration of action, suggesting utility in Alzheimer’s disease therapeutics.3 While early studies focused on actions in the central nervous system, XE 991 can be used to explore the roles of KCNQ channels in neuronal regulation throughout the body.4
WARNING This product is not for human or veterinary use.
1. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-
2. Molecular basis for differential sensitivity of KCNQ and IKs channels to the cognitive enhancer XE991. Mol. Pharmacol. 57(6), 1218-1223 (2000).
3. Two new potent neurotransmitter release enhancers, 10,10-
4. KCNQ channels determine serotonergic modulation of ventral surface chemoreceptors and respiratory drive. J. Neurosci. 32(47), 16943-16952 (2012).